Generic Medicine Info
Indications and Dosage
Acute allograft rejection in organ transplant recipients
Adult: 5 mg daily as IV bolus inj for 10-14 days. Risk of cytokine release syndrome or hypersensitivity reactions may be reduced by pre-treatment with methylprednisolone.
Child: As IV bolus inj: ≤30 kg: 2.5 mg daily, if necessary, may be increased by a further 2.5 mg. >30 kg: 5 mg daily. Doses should be given for 10-14 days.
Patients with pre-existing fever or uncontrolled hypertension. Hypersensitivity to products of murine origin. Avoid in patients with a history of seizures. Patients with uncompensated heart failure or who have undergone a more than 3% weight gain in the wk preceding therapy or who have radiographic evidence of fluid overloading. Pregnancy and lactation.
Special Precautions
Increases the risk of infections and certain malignancies. Caution when using IUDs due to an increased risk of infection. Avoid use of live vaccines. Repeated courses may be less effective due to formation of antibodies to the drug. Unstable angina, recent MI, ischaemic heart disease, heart failure, pulmonary oedema, COPD, vascular overload or depletion, septic shock, cerebrovascular disease, advanced symptomatic vascular disease or neuropathy, history of thrombotic events or underlying vascular disease. Children with primary Epstein-Barr viral infection. Assess volume status prior to therapy. Perform baseline and periodic renal, hepatic and haematopoietic tests. Monitor closely over 24 hr following each of the 1st few doses. Child ≤16 yr. If hypersensitivity is suspected, discontinue immediately and do not re-challenge.
Adverse Reactions
Diaphoresis, vasodilation, anorexia, asthenia, chills, fatigue, lethargy, malaise, fever, arrhythmia, bradycardia, hypertension, hypotension, chest pain, tachycardia, vascular occlusion, convulsions, dizziness, headache, meningitis, tremor, diarrhoea, nausea, abdominal pain, vomiting, anaemia, leukocytosis, thrombocytopenia, oedema, arthralgia, myalgia, confusion, depression, nervousness, somnolence, renal dysfunction, abnormal chest sound, dyspnoea, hyperventilation, hypoxia, pneumonia, pulmonary oedema, respiratory congestion, wheezing, pruritus, rash, photophobia, tinnitus, leucopenia.
IV/Parenteral: C
Symptoms include hyperthermia, severe chills, myalgia, vomiting, diarrhoea, oedema, oliguria, pulmonary oedema, acute renal failure and microangiopathic haemolytic anaemia. Patients should be observed closely and supportive treatment given if necessary.
Drug Interactions
Increased toxicity with immunosuppressants (e.g. azathioprine, corticosteroids, ciclosporin). Increased risk of encephalopathy and CNS effects with indometacin.
Description: Muromonab-CD3 is a mouse monoclonal antibody against CD3 (T3). It binds to T-cell receptor-associated CD3 complex and depletes and alters T-cells. Thus, it exerts an immunosuppressant effect without affecting the bone marrow.
Store at 2-8°C. Do not freeze or shake.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Muromonab-CD3 from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in